Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 50Breast Neoplasms 50Carcinoma, Non-Small-Cell Lung 48Prostatic Neoplasms 47Squamous Cell Carcinoma of Head and Neck 37Lung Neoplasms 30Head and Neck Neoplasms 26Glioma 23Rectal Neoplasms 22Sarcoma 20Neoplasms 20Brain Neoplasms 20Oropharyngeal Neoplasms 16Esophageal Neoplasms 15Uterine Cervical Neoplasms 14Neoplasm Metastasis 14Astrocytoma 14Esophageal Squamous Cell Carcinoma 13Triple Negative Breast Neoplasms 12Carcinoma, Hepatocellular 12Pancreatic Neoplasms 11Melanoma 11Gliosarcoma 10Colorectal Neoplasms 10Stomach Neoplasms 9Small Cell Lung Carcinoma 9Lymphoma 9Hodgkin Disease 9Carcinoma, Squamous Cell 9Urinary Bladder Neoplasms 8

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Radiotherapy × 1 year × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡